Second Opinion: Cost of Care for Non-Small Cell Lung Cancer

Dr. Rachel Sanborn and Yousuf Gaffar discuss the cost of care in advanced NSCLC, frontline treatment options for patients without driver mutations, and optimal adverse effect management strategies for approved immunotherapy regimens.